Rasna Therapeutics, Inc. filed its 10-K/A on Jun 10, 2022 for the period ending Sep 30, 2021. In this report its auditor, Marcum LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0016 USD | -82.22% |
|
-82.22% | -79.22% |
1st Jan change | Capi. | |
---|---|---|
-79.22% | 1.23M | |
+16.01% | 121B | |
+20.67% | 114B | |
+17.41% | 23.61B | |
-18.68% | 20.43B | |
-15.64% | 16.55B | |
-12.93% | 16.45B | |
-44.35% | 15.59B | |
+69.40% | 15.19B | |
+2.38% | 13.54B |
- Stock Market
- Equities
- RASP Stock
- News Actavia Life Sciences, Inc.
- Rasna Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt